ARTICLE | Clinical News
Invega Sustenna regulatory update
October 1, 2012 7:00 AM UTC
Johnson & Johnson's Janssen Pharmaceuticals Inc. unit said FDA approved an sNDA to update the label of schizophrenia drug Invega Sustenna to include an extended dosing window to help avoid missed dose...